ERBB2 and ductal breast carcinoma in situ: Thorat et al. demonstrated that HER2-positive DCIS patients substantially benefited from adjuvant radiotherapy in comparison with HER2-negative DCIS patients, with a greater reduction in in situ recurrences, but not in invasive recurrences [12].